<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040950</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069423</org_study_id>
    <secondary_id>UCLA-0112032</secondary_id>
    <secondary_id>CPGI-C004-CPG7909</secondary_id>
    <secondary_id>NCI-G02-2086</secondary_id>
    <nct_id>NCT00040950</nct_id>
  </id_info>
  <brief_title>Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Multi-Center, Phase I, Open Label, Two Arm, Non-Randomized, Dose-Escalation, Study Of The Safety And Tolerability Of CPG 7909 In Patients Receiving Rituxan For Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill&#xD;
      them or deliver cancer-killing substances to them without harming normal cells. Biological&#xD;
      therapies such as CpG 7909 use different ways to stimulate the immune system and stop cancer&#xD;
      cells from growing. Combining CpG 7909 with rituximab may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of CpG 7909 plus rituximab in treating&#xD;
      patients who have relapsed or refractory non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of subcutaneous and IV CpG 7909 when administered&#xD;
           with rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the disease response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of CpG 7909. Patients are sequentially&#xD;
      assigned to 1 of 2 treatment groups.&#xD;
&#xD;
        -  Group A: Patients receive rituximab IV over 4-5 hours followed by CpG 7909 IV over 2&#xD;
           hours on day 1. Courses repeat weekly for 4 weeks.&#xD;
&#xD;
        -  Group B: Patients receive rituximab as above followed by CpG 7909 subcutaneously on day&#xD;
           1. Courses repeat weekly for 4 weeks.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of CpG 7909 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3&#xD;
      or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-48 patients (3-24 per treatment group) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>agatolimod sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed CD20+ B-cell non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  CD20 positive by immunohistochemistry or flow cytometry&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  Sole site of measurable disease within a previously irradiated field allowed&#xD;
                  provided there was disease progression at that site&#xD;
&#xD;
          -  No pre-existing ascites or pleural effusions&#xD;
&#xD;
          -  No known CNS involvement by NHL&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2 mg/dL&#xD;
&#xD;
          -  Transaminase less than 2 times upper limit of normal&#xD;
&#xD;
          -  No hepatitis B or C&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
          -  No New York Heart Association class III congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No uncontrolled atrial or ventricular cardiac arrhythmias&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No concurrent significant pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No acute infection requiring antibiotics&#xD;
&#xD;
          -  No fever over 38.2 degrees C within the past 3 days&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell or noninvasive squamous&#xD;
             cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No pre-existing autoimmune disease or antibody-mediated disease, including:&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Sjogren's syndrome&#xD;
&#xD;
               -  Autoimmune thrombocytopenia&#xD;
&#xD;
          -  Controlled thyroid disease allowed&#xD;
&#xD;
          -  Concurrent autoantibodies without clinical autoimmune disease allowed&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar composition to&#xD;
             study drugs&#xD;
&#xD;
          -  No other medical history, including laboratory results, that would preclude study&#xD;
&#xD;
          -  No suspected or confirmed poor compliance or mental instability that would preclude&#xD;
             study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior allogeneic transplantation&#xD;
&#xD;
          -  More than 30 days since prior hematopoietic growth factors (e.g., filgrastim (G-CSF)&#xD;
             or epoetin alfa)&#xD;
&#xD;
          -  More than 30 days since prior immunotherapy&#xD;
&#xD;
          -  More than 90 days since prior monoclonal antibodies as monotherapy for patients who&#xD;
             were unresponsive to treatment (30 days for patients who responded to treatment and&#xD;
             subsequently relapsed)&#xD;
&#xD;
          -  No other concurrent biological agents&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors (e.g., G-CSF or epoetin alfa)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  More than 30 days since prior systemic corticosteroids&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 30 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 6 months since prior coronary angioplasty&#xD;
&#xD;
          -  More than 30 days since prior immunosuppressants&#xD;
&#xD;
          -  More than 30 days since prior participation in an investigational drug study&#xD;
&#xD;
          -  No concurrent immunosuppressants&#xD;
&#xD;
          -  No concurrent anticoagulants except aspirin at doses no greater than 325 mg/day&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos E. Emmanouilides, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007 Oct 15;13(20):6168-74.</citation>
    <PMID>17947483</PMID>
  </results_reference>
  <verification_date>July 2003</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

